Carole Nuechterlein - Jun 23, 2022 Form 4 Insider Report for Aligos Therapeutics, Inc. (ALGS)

Role
Director
Signature
/s/ Lucinda Y. Quan, as attorney-in fact for Carole Nuechterlein
Stock symbol
ALGS
Transactions as of
Jun 23, 2022
Transactions value $
$0
Form type
4
Date filed
6/27/2022, 04:12 PM
Previous filing
Jun 6, 2022
Next filing
Jul 21, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALGS Stock Option (Right to Buy) Award $0 +15K $0.00 15K Jun 23, 2022 Common Stock 15K $1.34 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2023 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.